IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
20 Setembro 2023 - 9:00AM
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage
biopharmaceutical company focused on innovative gamma-delta T cell
therapies, today announced William Ho, CEO and co-founder, will
participate in a panel presentation at the 2023 Cantor Fitzgerald
Global Healthcare Conference on Wednesday, September 27, 2023, at
8:35 a.m. ET.
The Cantor Fitzgerald presentation will be
available live and as a replay on IN8bio’s website at
https://bit.ly/3F1WEaQ.
About IN8bioIN8bio is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of gamma-delta T cell product
candidates for solid and liquid tumors. Gamma-delta T cells are a
specialized population of T cells that possess unique properties,
including the ability to differentiate between healthy and diseased
tissue. IN8bio’s DeltEx platform employs allogeneic, autologous,
iPSC and genetically modified approaches to develop cell therapies,
designed to effectively identify and eradicate tumor cells.
IN8bio is currently conducting two
investigator-initiated Phase 1 clinical trials for its lead
gamma-delta T cell product candidates: INB-200 for the treatment of
newly diagnosed glioblastoma and INB-100 for the treatment of
patients with hematologic malignancies undergoing haploidentical
hematopoietic stem cell transplantation. IN8bio is initiating
INB-400, a company-sponsored multi-center Phase 2 clinical trial in
newly diagnosed glioblastoma, which received IND clearance in late
2022. IN8bio also has a broad portfolio of preclinical programs
focused on addressing other hematological and solid tumor cancers.
For more information about IN8bio and its programs, please visit
www.IN8bio.com.
Company Contact:IN8bio,
Inc.Patrick McCall+ 1 646.600.6GDT (6438)info@IN8bio.com
Investors & Media
Contact:Argot PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024